ATTD 2026: This 12-minute presentation explores perspectives on CGM use in prediabetes and type 2 diabetes.
This resource is intended for educational purposes only for healthcare providers practicing in the United States. It does not constitute medical advice and is not a substitute for professional judgment or individualized patient care.
In this 12-minute presentation, Dr. Viral Shah explores the value of early CGM adoption, discusses a staged approach to prediabetes and T2D, and highlights how CGM can help address clinical inertia and support earlier interventions.
This presentation is part of the Transforming Diabetes Care:The Power of Dexcom CGM from Prediabetes to Insulin Therapy session, recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) 2026 in Barcelona, Spain on March 13, 2026.
